scispace - formally typeset
V

Vladimir Tesar

Researcher at First Faculty of Medicine, Charles University in Prague

Publications -  307
Citations -  22066

Vladimir Tesar is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Medicine & Kidney disease. The author has an hindex of 48, co-authored 256 publications receiving 17061 citations. Previous affiliations of Vladimir Tesar include Charles University in Prague.

Papers
More filters
Journal ArticleDOI

Effect of Hemodiafiltration on Pregnancy-Associated Plasma Protein A (PAPP-A) and Related Parameters

TL;DR: A single hemodiafiltration session compared to HD has no advantage in the decrease of PAPP-A and other tested molecules, all of them related to cardiovascular risk.
Journal ArticleDOI

Detailed assessment of renal function in a proband with Harboyan syndrome caused by a novel homozygous SLC4A11 nonsense mutation.

TL;DR: In contrast to the Slc4a11-/- mouse, no abnormalities in daily renal ion excretion or polyuria were observed in the Harboyan syndrome patient and the mutation identified does not affect corneal endothelial cell morphology or density in the heterozygous state.
Journal Article

Effects of sodium restriction and cyclooxygenase-2 inhibition on the course of hypertension, proteinuria and cardiac hypertrophy in Ren-2 transgenic rats.

TL;DR: The present data indicate that TGR exhibit an important salt-sensitive component in the developmental phase of hypertension and suggest that systemic COX-2-derived prostaglandins do not act as vasodilatory counterregulatory agents in TGR.
Journal ArticleDOI

Reduction of arteriovenous access blood flow leads to biventricular unloading in haemodialysis patients

TL;DR: In this paper, the authors investigated the early effect of surgical AVF blood flow reduction on these changes in patients with or without heart failure changes and found that the beneficial effect of AVF reduction is present even in patients without symptoms of heart failure.
Journal ArticleDOI

Belimumab in the management of systemic lupus erythematosus – an update

TL;DR: This manuscript evalues the recent data concerning belimumab’s safety and clinical effectiveness and its current place in the treatment of SLE with serologic activity and clinical activity namely in mucocutaneous and musculoskeletal domains despite standard of care treatment.